Pharmaceuticals - Union Register

  

Register of orphan medicinal products


GRANTED  

Product information

Rilotumumab

EU orphan designation number: EU/3/14/1291   
Active ingredient: Rilotumumab
Indication: Treatment of gastric cancer
Sponsor: Amgen Europe B.V.
Minervum 7061, 4817 ZK Breda, Nederland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
31/07/2014 Orphan designation EMA/OD/012/14 (2014)5518 of 29/07/2014